While blood pressure (BP) 'track' from childhood into adult life, how differential growth in early life affects the BP course in early childhood is unclear, as is how BP develops over time of smaller infants who catch up. We report the impact of early growth from a birth-4y study comparing local, smaller South Asian (SA) & European children.
Over 400 children (26% SA) followed from birth had growth & BP measures at 3 or 6 months, &/or 1, 2, & 4 years, using standardised methods on a validated Dynamap oscillometer, mean of 2 readings with appropriate cuffs. SA children were some 300 g lighter, 1 cm shorter at birth than Europeans, catching up in weight by 3 months and length by 1y (both groups exceeding 1990 national means), which predicted BP at 1y.
Mean BPs stabilised over the next 3y, from 92.7-94.6/56.7-61.7 mm Hg in in SA. In mixed longitudinal analyses over time, systolic BP was 1.7 (95%CI 0.2-3.1) mm Hg lower in girls but in both sexes, subscapular & triceps skinfold thickness displaced height and weight as BP drivers, 0.6-0.9 (CI 0.2-1.5) mm Hg per unit (Po0.006), adjusted for other factors. Results for diastolic BP were even stronger at nearly 1 mm Hg from each (Po0.004), with height also retained. A core group of 38-53 children had fully longitudinal measures; by 4y, BP drivers were still height growth from 0-1y, with ethnic effects. Conclusion: Early weight gain, with increased subcutaneous fat in early years, may be a major driver of later BP. Oxidative stress is implicated in the pathogenesis of hypertension and stroke. Superoxide (SO) is produced by NAD(P)H oxidase. The anti-oxidant peptide gp91ds selectively inhibits NAD(P)H oxidase, thereby reducing SO production. 1 Vascular targeting peptides CRPPR and CSGMARTKC were identified by phage display in mice.
Targeted anti-oxidant therapy in a model
2 These peptides retain their selectivity across species and target the aorta (CRPPR) and cardiac vasculature (CSGMARTKC) in a model of human essential hypertension, the strokeprone spontaneously hypertensive rat (SHRSP). Therefore, we wished to assess whether linkage of gp91ds to a vascular targeting peptide could increase the anti-oxidant effect in the SHRSP.
Systolic blood pressure (SBP) was determined for one week prior to treatment, followed by three weeks of study duration before sacrifice. SBP showed a progressive rise from 177.5 ± 1.5 to 200.2 ± 0.8 mm Hg in those groups receiving CSGMARTKC, gp91ds and gp91ds-HIV-tat (to allow entry to all cells). This SBP increase was prevented in animals receiving CRPPR (SBP 187.5 mm Hg±5.2, *Po0.01 vs HIV-tat and gp91ds treated groups). Additionally, CRPPR-, CSGMARTKC-gp91ds and gp91ds alone showed significantly improved nitric oxide (NO) bioavailability determined by large vessel myography, whereas HIV-tat treated animals continued to show impaired endothelial function characteristic of the SHRSP.
Therefore, anti-oxidant therapy alone shows improvement in NO bioavailability. However, when targeted with CRPPR, a significant improvement in NO bioavailability and attenuation of the time dependent and progressive increase in SBP in the SHRSP is observed.
Resting heart rate pattern during follow-up and mortality in hypertensive patients L Paul, C Hastie, GT McInnes and S Padmanabhan

BHF Glasgow Cardiovaascular Research Centre, Glasgow, United Kingdom
There is a linear relationship between resting heart rate (HR) and mortality in normotensive and untreated hypertensive individuals. However it is not clear whether heart rate is a marker of increased risk in hypertensive patients on treatment.
We studied 3364 patients attending the Glasgow Blood Pressure Clinic with a mean follow-up duration of 4 years and documented heart rate at each visit. Using a threshold of 80 bpm, we classified patients into those who had a consistently high (high-4high) or low (low-4low) HR or whose HR increased (low-4high) or HR decreased (high-4low) during follow-up. Patients who had been prescribed ratelimiting therapy (beta blockers/non-dihydropyridine CCB) and who continued with this therapy for at least 1 year were defined as being on rate-limiting therapy. Mortality data was obtained from the registrar general through record linkage and there were 304 deaths over 15 years. Survival analysis was carried out using Cox propotional hazards model adjusted for age, gender, BMI, smoking, rate-limiting therapy, systolic blood pressure and serum cholesterol. Compared to low-4low patients, high-4high patients had a 78% increased risk of all-cause mortality (HR 1.78; 95% CI 1.31-2.41; Po0.001). The next highest risk group was low-4high (1.52; 1.0-2.3) followed by high4low (1.19; 0.87-1.64). The results followed the same pattern for cardiovascular mortality. Rate limiting therapy did not have an independent effect on outcomes in this analysis.
We show that change in HR over the follow-up period in treated hypertensive patients is a marker of risk and may be a better predictor than single point HR analysis.
Introduction:
The renin-angiotensin-aldosteronesystem is implicated in obesity and hypoxia. We tested the hypothesis that aldosterone causes a loss of the normal anticontractile function of perivascular fat via an hypoxia-related pathway. Methods: Healthy rat mesenteric arteries (B250 mM) were studied by wire myography. Effects of aldosterone and antagonists were assessed following 10 min and 3 h incubation, and 2.5 h hypoxia (95%N 2 /5%CO 2 ). Results: Healthy fat had an anticontractile effect on arteries (no fat: 153±6%; fat: 90±4%, n ¼ 36) which was lost following incubation with aldosterone (10 min: 165 ± 5%, n ¼ 25, 3 h: 172 ± 12%, n ¼ 7). Eplerenone, but not spironolactone restored contractility following 10 min aldosterone incubation (eplerenone: 89 ± 3%, n ¼ 7), whereas spironolactone was more effective at reversing the effects of 3 h incubation with aldosterone (spironolactone: 103 ± 8%, n ¼ 5). Incubation with both antagonists had a synergistic effect (101±9%). Incubation with the free radical scavengers superoxide dismutase and catalase rescued the effect of 3 h aldosterone incubation (99 ± 9%, n ¼ 5).
Experimental hypoxia attenuated the anticontractile effect, which was restored by incubation with eplerenone, although spironolactone only had a marginal effect (hypoxia: 149±4% n ¼ 15, hypoxia þ eplerenone: 101 ± 14% n ¼ 7). Conclusions: Aldosterone and hypoxia affect the anticontractile property of fat by a common pathway, because aldosterone antagonists are able to inhibit the response to hypoxia in the absence of aldosterone and the effects of aldosterone were reversed by free radical scavengers. We believe the contrast in efficacy of the two antagonists is due to differences in specificity for the mineralocorticoid receptor, which is currently under investigation.
2.6. Self blood pressure monitoring is the future of hypertension management
N McGowan and P Padfield
Western General Hospital, Edinburgh, United Kingdom Ambulatory blood pressure measurement (ABPM) is regarded by many as the 'gold standard' in blood pressure measurement. However, it is not without problems. It is expensive, disliked by many patients and requires trained staff. Also, despite published guidelines, experts cannot agree how ABPM should be interpreted.
Both European and American Societies have endorsed self blood pressure monitoring (SBPM) in the management of hypertension but uncertainty remains regarding the potential equivalence of SBPM with ABPM.
We compared the methodologies in 87 consecutive patients referred for ABPM. All underwent a week of SBPM as defined by ESH guidelines, either immediately before or after ABPM. There was no significant difference in mean BP with either technology (mean awake ABP 141/86 mm Hg (±11/10) & SBPM 142/ 87 mm Hg (±12/10), P ¼ ns). In terms of diagnostic category, 13% of subjects switch category from hypertensive (X135/85 mm Hg) to normotensive (o135/85 mm Hg) or vice versa when a different type of monitor is used. However, when ABPM is repeated within one year (data on 96 patients from our ABPM database), 8% of subjects switch categories (P ¼ ns as compared with SBPM vs ABPM).
No method of BP measurement is 100% reproducible and we have demonstrated SBPM is as accurate as repeated episodes of ABPM. In addition, SBPM is preferred by 81% of subjects, it is considerably cheaper than ABPM and only requires a third of the nursing time compared to ABPM.
SBPM should become the new reference standard for assessment of blood pressure and offers a completely new way of managing patients with hypertension.
3.1. In vivo evidence that SPAK is a new regulator of blood pressure 3.3. The thiazide-sensitive Na-Cl cotransporter in the distal nephron (NCCT) is regulated by both kinases and phosphatases
M Glover and KM O'Shaughnessy
University of Cambridge, Cambridge, United Kingdom Dissecting the molecular regulation of renal sodium transport by the thiazide-sensitive NCCT has provided important insights into the mechanisms underlying hypertension. NCCT regulation is orchestrated by a scaffold of proteins including SPAK and WNK4 kinases. Intuitively such dynamic regulation must also involve phosphatases. Two distinct phosphorylation controlled regulatory pathways for NCCT exist; Type 1 mediated by WNK3/4 affecting trafficking to the surface membrane and Type 2 involving modulation of intrinsic transporter kinetics by phosphorylation of N-terminal amino acids e.g. T58. In addition the design of WNK kinase inhibitors has been hampered partly by steric constraints of key residues blocking entry of small molecule inhibitors to the active site of the enzyme.
To address this we used site mutation to produce constructs of NCCT T58D/A, kinase-dead PP4 and WNK4-T261A. Xenopus oocytes were then injected with cRNA from these constructs and NCCT expression followed using 22 Na þ flux and confocal microscopy.
PP4 expression inhibited NCCT activity by 68% without affecting surface membrane expression. The effect was specific to PP4 and dependent on both its phosphatase activity and NCCT-T58 to accept the phosphate. Phosphatases did not affect WNK4 regulation of NCCT membrane trafficking. In addition, site mutation of WNK4 T261A enhanced fifteen fold its susceptibility to the kinase inhibitors SB202190 and SB203580.
Thus NCCT activity but not trafficking is regulated by PP4 with clear implications for blood pressure control. Furthermore, single site mutation of WNK4 increases significantly its sensitivity to established kinase inhibitors increasing the prospects for pharmacological investigation of this pathway in vivo. Mitochondria are implicated as a source of vascular superoxide production in cardiovascular disease (CVD). It has also been suggested that mitochondrial ROS may activate AMPK. We investigated mitochondrial ROS production in intact saphenous veins and primary saphenous vein endothelial cells (HSVECs) from patients with CAD and healthy control subjects.
Portions of vessels were obtained from patients undergoing coronary artery bypass grafting (n ¼ 54) and varicose vein removal (n ¼ 19) and HSVECs isolated and cultured from selected vessels. Endothelial function was assessed by relaxation to calcium ionophore A23187 and vascular superoxide production measured using lucigenin-enhanced chemiluminescence. AMPK activity was assayed via radioactively-labelled ATP incorporation.
Endothelium-dependent vasodilation was impaired in patients with CAD compared to control subjects (maximum relaxation, 43 ± 16 vs 62 ± 16%; Aortic pulse wave velocity (PWV) is an independent predictor of cardiovascular risk. However, PWV is usually determined between the carotid and femoral sites, ignoring the proximal ascending aorta which may stiffen most with age. We tested this hypothesis by assessing regional PWV along the length of the entire aorta using MRI. 147 healthy subjects aged 18-79 years, all free of cardiovascular disease and medication, were recruited from the ACCT study. Seated and supine blood pressure was measured and carotid-femoral pulse wave velocity (PWV Sphyg ) was assessed by applanation tonometry (SphygmoCor, Australia). Phase contrast MRI (PCMRI) (1.5T scanner, GE) was then performed in all patients to determine PWV (PWV MRI ) in 4 aortic regions, the arch (R1), descending-thoracic (R2), mid-thoracic (R3) and abdominal aorta (R4). Repeatability of PWV MRI was assessed across 2 visits, in a subset of 10 subjects.
PWV MRI over the length of the whole aorta (aPWV MRI ) was compared with PWV Sphyg as validation.
The average PWV MRI for R1 to R4 were 4.6 ± 1.5, 5.5 ± 2.0, 5.7 ± 2.3, and 6.1 ± 2.9 m/s respectively. There was no difference between genders. The greatest age-related increase in PVW MRI occurred in R4 (0.9 m/s per decade, Po0.001) followed by R2 (0.7 m/s, Po0.001), R3 (0.6 m/s, Po0.001) and R1 (0.4 m/s, Po0.001). PWV MRI showed good repeatability (mean difference ¼ À0.4 ± 2.1 m/s). aPWV MRI and PWV Sphyg were strongly correlated (r ¼ 0.71, Po0.001), although overall aPWV MRI was significantly lower than PWV Sphyg (5.7 ± 1.8 vs 7.3 ± 1.8 m/s, Po0.001).
Age-related increases in arterial stiffness are greatest in the descending and abdominal aorta. Measurements of PWV using PCMRI are reproducible and correlate with surface measurements of PWV.
3.6. Two common polymorphic haplotypes exist in the region of human chromosome 8 containing the CYP11B1 (11b-hydroxylase) and CYP11B2 (aldosterone synthase) genes. We and others have previously shown that the polymorphisms found on Haplotype1 associate with increased aldosterone production, a greater risk of developing hypertension and reduced 11b-hydroxylation efficiency. Haplotype2 contains the alternate form of these polymorphisms.
Using an allele-specific RT-PCR method and RNA isolated from human adrenal tissue samples heterozygous for these haplotypes, we investigated whether the Haplotype1 forms of CYP11B1 and CYP11B2 were transcribed at significantly different levels than those of Haplotype2. mRNAs derived from the Haplotype1 form of the CYP11B1 gene were found to be significantly less abundant than their Haplotype2-derived counterparts in all of the tissues examined (n ¼ 5, Po0.01), accounting for B41% of total CYP11B1 mRNAs. Conversely, Haplotype1-derived CYP11B2 mRNAs were significantly more abundant than the Haplotype2 form (n ¼ 5, Po0.02), totalling B60% of all CYP11B2 mRNAs.
These data suggest that the CYP11B1 gene on Haplotype1 is transcribed at a lower level than that on Haplotype2, providing an explanation for the lower 11b-hydroxylation efficiency that associates with Haplotype1. Similarly, the higher transcription rate of the CYP11B2 gene on Haplotype1 provides a plausible explanation for that haplotype's association with increased aldosterone production and a greater risk of developing hypertension with a raised aldosterone to renin ratio. These data are therefore consistent with a digenic effect leading to increased aldosterone secretion and decreased 11b-hydroxylation.
4.1. Relationship between preterm delivery and subsequent C-reactive protein and ischaemic heart disease risk Objective: Previous studies have suggested an association between preterm delivery and subsequent maternal IHD risk. We explored this further by examining separately the associations between spontaneous and elective preterm delivery and both IHD events and levels of C reactive protein.
Methods:
We linked three Scottish routine data sources. The Scottish Health Survey (lifestyle risk factors including blood samples), Scottish Morbidity Record (all acute hospital admissions and all pregnancies) and death certificate data.
Univariate and multiple linear regression analyses were used to study the association between preterm delivery and CRP. Univariate and multivariate Cox proportional hazards models were used to explore the associations between preterm delivery and IHD outcomes. Results: On multivariate analysis, there was a significant overall association between preterm delivery and CRP (beta ¼ 0.053, Po0.05). On subgroup analysis, this association was specific to elective preterm delivery (beta ¼ 0.007, Po0.01). There was no significant association with spontaneous preterm delivery.
We observed an independent association between preterm delivery and all three IHD outcomes (all cause deaths HR 1.57, 95% CI 1.47-1.68, IHD deaths HR 2.23, 95% CI 1.74-2.85, IHD events HR 1.69, 95% CI 1.53-1.86). On sub-group analysis, associations were much stronger for elective preterm delivery than spontaneous preterm delivery. Conclusions: Elective preterm delivery is usually undertaken because of growth restriction or preeclampsia and is therefore a marker of placental dysfunction. Spontaneous delivery is due to other causes such as infection. Our results suggest a common mechanism predisposing to both placental dysfunction and ischaemic heart disease. The association with CRP suggests this may be mediated via inflammation. The exciting discovery of a vasodilatory arm to the renin-angiotensin system (RAS) that directly opposes the classical vasoconstrictor actions of angiotensin II (AngII) has stimulated considerable interest. We have recently demonstrated that chronic low dose AngII infusion in females, at a dose which had no effect on mean arterial pressure (MAP) in males, decreased MAP by B10 mm Hg, a response that was mediated by the AngII type 2 receptor (AT 2 R). 1 Given that estrogen is known to differentially regulate components of the RAS, shifting the balance of vasodilator to vasoconstrictor components towards vasodilation, we hypothesised that the depressor response to low dose AngII in females would be estrogen dependent. Females underwent sham or ovariectomy surgery (OVX) and were treated with placebo or an estrogen pellet. MAP was measured via radiotelemetry during saline or AngII infusion (50 ng/kg/min s.c.). AngII and Mas receptors (AT 1a R, AT 1b R, AT 2 R and MasR) were quantified using real-time PCR. AngII decreased MAP in intact females (À10 ± 2 mm Hg), a response that was abolished by OVX ( þ 4±2 mm Hg) and restored by estrogen replacement (À6 ± 2 mm Hg). Furthermore, there was a shift in the renal and aortic ratio of vasodilator (AT 2 R and MasR) to vasoconstrictor (AT 1a R and AT 1b R) components in estrogen treated females towards vasodilation compared to OVX females. We suggest that in females, estrogen dependent mechanisms counteract the pressor actions of AngII by enhancing the recently discovered vasodilator pathways of the RAS. This highlights the potential for these vasodilator pathways as therapeutic targets, particularly in women. Background: The population benefits of dietary salt reduction, a major public health intervention, have been extrapolated by those expected through its blood pressure lowering effect. Objectives: To perform a systematic review of the prospective studies that assessed the relationship of the level of habitual salt intake to stroke and/or cardiovascular outcomes, and to obtain an estimate of risk.
Ang II-induced hypotension in females is
Methods: We performed a systematic search of publications through online databases and relevant reviews. According to pre-defined selection criteria, 13 studies were included in the meta-analysis. For each study, relative risks and 95% CI were extracted and pooled using a random effect model, weighting for the inverse of the variance. Sensitivity analysis was performed, heterogeneity and publication bias were assessed.
Results: Overall, there were 19 independent cohort samples, with 177 025 participants (follow-up range 3.5-19 years) and over 11 000 vascular events. In the pooled analysis, higher salt intake was associated with greater risk of stroke (RR: 1.23; 95% CI 1.06-1.43; P ¼ 0.007) and CVD (1.14; 0.99-1.32; P ¼ 0.07), with no evidence of publication bias but significant heterogeneity between studies. For stroke the pooled estimate did not vary substantially with the exclusion of individual studies. However, for CVD the exclusion of a single study led to a pooled estimate of 1.17 (1.02-1.34); P ¼ 0.02. Conclusion: High salt intake is associated with significantly greater risk of both stroke and total CVD. These results support worldwide recommendations for a population reduction in salt intake to prevent cardio and cerebrovascular disease. Addenbrooke's Hospital, Cambridge, United Kingdom
In the SALT study of low-renin hypertension, highdose amiloride had similar efficacy to bendroflumethiazide (bfz) in reducing BP, but twice the efficacy in 'de-suppressing' plasma renin. 1 We hypothesized that thiazides are not purely natriuretic, and that low-dose combination with amiloride should be more effective than high-dose single diuretics. 32 young, low-renin patients rotated in random order through 5-week cycles of once-daily amiloride 40 mg, bfz 5 mg, spiro(nolactone) 100 mg, frusemide 40 mg, combo (bfz 2.5 mg þ amiloride 20 mg) and placebo. Endpoints were home-SBP (12 readings, a.m./p.m., over 3 days), and plasma-renin. A substudy compared simultaneous with alternate dosing of bfz þ amiloride.
BP fell more on low-dose combo than on highdose single drugs (Po0.05). The superiority was even greater when bfz þ amiloride were alternately dosed. Plasma-renin rose much higher on K þ -sparing than on other single diuretics (Po0.01), with further increase on combo -except in two patients where, despite normal K þ and aldo(sterone) at baseline, hypokalaemia on bfz unmasked a Conn's adenoma. One patient required treatment, pre-adrenalectomy, with spiro (25 mg Background: In patients with Type 2 Diabetes (T2D), small artery endothelial dysfunction and loss of myogenic autoregulation may be relevant to downstream microvascular target organ damage. Metabolic Syndrome (MS) is an intermediate phenotype in the development of T2D and also is associated with target organ damage. Although small artery function has been suggested as cause for this, mechanisms are unclear. Here we present the first study of small artery structure and function with assessment of target organ damage in patients with MS. Methods and Results: 37 patients (with MS (n ¼ 20), without MS (n ¼ 17)) underwent cardiovascular profiling, echocardiography and subcutaneous gluteal fat small artery study. Patients with MS showed evidence of early diabetic cardiac disease with diastolic dysfunction (Lateral E:E 0 ratio: MS:9 vs NoMS:5.8, P ¼ 0.004) but preservation of systolic function.
Patients were matched for age, blood pressure and treatments to modify the renin-angiotensin axis and statin therapy. Small arteries from patients with MS showed endothelial dysfunction which was only partly accountable by downregulation of nitric oxide synthase. Myogenic autoregulation of arteries was damaged, although to a lesser extent than that seen in patients with T2D. There were no differences in small artery structure or distensibility. Conclusions: MS is associated with damage to small artery myogenic autoregulation in addition to endothelial dysfunction. Although the arteries studied were from a different circulation to those involved in target organ damage, alterations to myogenic reactivity should be taken into consideration when considering the development of diastolic dysfunction and microvascular complications in patients with MS.
5.3. Aldosterone and sodium excess associate with albuminuria and glomerular hyperfiltration in a severely hypertensive cohort from the MRC BRIGHT study EM Freel loading. However, the renal consequences of aldosterone excess in humans are unclear. We aimed to explore the relationship between urinary aldosterone and sodium on creatinine clearance and albuminuria in a hypertensive subgroup from the BRIGHT (British Genetics of Hypertension) study. Five hundred and ten subjects performed 24-h urine collections for measurement of urinary aldosterone (tetrahydroaldosterone; THAldo), albumin and sodium excretion. Subjects were analysed according to aldosterone status ('high' top centile and 'low' bottom centile; n ¼ 95 in both groups) and salt intake based on tertiles of urinary sodium.
There was no significant difference in blood pressure between the groups (Po0.5). In the high THAldo group, urinary albumin excretion increased progressively across urinary sodium tertiles (Po0.05), there was a significant correlation between urinary sodium and albumin excretion (r ¼ 0.256, Po0.02) as well as creatinine clearance and THAldo excretion (r ¼ 0.235, Po0.02). Creatinine clearance also increased progressively across urinary sodium tertiles in the high THAldo group (Po0.0001). These relationships were not found in the low THAldo group. Finally, creatinine clearance was significantly higher in the high THAldo than low THAldo groups (Po0.0001).
In hypertensive subjects, aldosterone excess combines with sodium to increase albuminuria; increased urinary aldosterone also associates with an increase in creatinine clearance suggestive of glomerular hyperfiltration (early indication of renal damage). These results confirm that aldosterone (with sodium) makes a significant contribution to renal impairment in essential hypertension. Using data from the ASCOT trial we developed a new risk score for predicting the 5-year risk of a first cardiovascular (CV) event in hypertensive patients receiving contemporary treatment practices (increased use of statins, and more intensive blood pressure (BP) control). The composite primary outcome was: CV death, MI or stroke. We used baseline variables of age, sex, smoking, diabetes, previous treatment, SBP, total cholesterol, HDL, glucose and creatinine to fit a Cox proportional-hazard model (ASCORE). We also fitted a 'simplified' model that doesn't contain laboratory variables (ASCORE-S). After an internal validation, we used the INDANA dataset (a database of 10 trials published prior to 1995) for external validation. The ASCORE-S predicted the same gradient in risk but far fewer events than actually observed in INDANA. A possible explanation is that treatment in ASCOT was considerably more effective in reducing BP and cholesterol. We re-estimated the expected rates of events in INDANA, had the patients experienced similar reductions in BP and lipids as seen in ASCOT. These expected rates were now more similar to those predicted by ASCORE-S (see figure) . Hence the greater reductions in BP and lipids among ASCOT patients can reasonably explain why ASCORE-S predicts fewer events than actually occurred in INDANA. Conversely risk scores developed with older databases (such as INDANA) may over-predict the CV risk of individuals receiving current BP and lipid lowering treatments. We conclude that this 'new' risk score should be used to predict accurately the CV risk of hypertensive patients receiving contemporary management. 
ASCORE
A þ C þ D, are likely to have an activated renin system. Thus, this observational study evaluated the benefit of the direct renin inhibitor aliskiren in patients with RH. Methods: We invited a sample of UK general practitioners to provide data on patients recently treated with aliskiren. Of 571 aliskiren-treated patients, 67 patients were identified who: (i) had uncontrolled BP (4140/90 mm Hg) despite treatment with A þ C þ D; (ii) were subsequently treated with aliskiren; (iii) had no other changes to medication that might have influenced BP during the aliskiren treatment period. Mean patient age was 59.5 ± 1.7 yrs, 41.8% were male and 97% Caucasian. Results: Addition of aliskiren 150 mg daily to A þ C þ D reduced BP from baseline by 16.2/ 9.9 mm Hg over 12 weeks (Po0.01). For those titrated to 300 mg daily, the mean BP reduction from baseline was 22.4/9.6 mm Hg (Po0.01).
Conclusions: This observational study suggests aliskiren provides clinically significant BP reductions in RH, supporting the importance of renin in the development of RH. Limitations of observational studies are acknowledged but the magnitude of response suggests a novel treatment option for RH. Darusentan (DAR), a novel ETA-selective endothelin receptor antagonist, was recently shown to reduce mean systolic blood pressure (SBP) by 18 mm Hg in patients with resistant hypertension (RHTN) receiving optimized background therapy with X3 antihypertensive medications, including a diuretic. In study DAR-311, patients with guideline-defined RHTN were randomized to DAR 50, 100, or 300 mg or placebo (PBO) once daily for 14 weeks. Percent of patients achieving SBP goal was a predefined secondary endpoint, and additional responders analyses were prespecified measures of interest. After 14 weeks of treatment, DAR treatment significantly decreased SBP and diastolic blood pressure, and a higher proportion of DAR-treated patients achieved SBP goal (DAR 50, 53%; DAR 100, 53%; DAR 300, 48%) as compared to PBO-treated patients (27%) (Po0.001). More patients receiving DAR experienced decreases in SBP X20 mm Hg (DAR 50, 38%; DAR 100, 43%; DAR 300, 46%) as compared to PBO (17%), and more than 3 times as many DAR-treated patients achieved a blood pressure target of 120/80 (DAR 50, 16%; DAR 100, 20%; DAR 300, 25%) as compared to PBO (5%). The most frequently reported adverse events in DARtreated patients were related to fluid retention/ oedema; however, few resulted in discontinuation of study or study drug. One cardiac-related death occurred in a patient receiving placebo. Five DAR-treated patients experienced cardiovascular events: 2 had MI (both with prior history of CAD), 1 had recurrence of CHF that was present at baseline, and 2 had CHF with preserved ejection fractions that responded rapidly to diuretic therapy.
Aliskiren Baseline (BL) BP
PA.4. Relationship between therapeutic changes in blood pressure and outcomes in acute stroke: a meta-regression CM Geeganage and PMW Bath
University of Nottingham, Nottingham, United Kingdom
Background: Both low and high blood pressure (BP) during the acute phase of stroke are associated independently with a poor outcome. Several small trials have involved the alteration of BP and this study assessed the relationship between change in BP and functional outcome. Methods: Randomised controlled trials of interventions that would be expected, on pharmacological grounds, to alter BP in patients within one week of the onset of acute stroke were sought using electronic searches. Data were collected on BP and clinical outcome. The relationship between the difference in on-treatment BP and odds ratios (OR) for outcomes was assessed using metaregression. Results: 37 trials involving 9,008 patients were included. 'U' or 'J' shaped relationships were found between on-treatment BP difference and early death (o1 month), death at the end of 90 day follow up, and combined death or dependency at the end of follow up. Although outcomes were not significantly reduced at any level of change in BP, the lowest odds occurred: early death (OR 0.87, 95% confidence interval, CI 0.54-1.23) at 8.1 mm Hg; death at end of follow up (OR 0.96, 95% CI 0.31-1.65) at 14.4 mm Hg; and combined death or dependency at end of follow up (OR 0.95, 95% CI 0.11-1.72) at 14.6 mm Hg. Conclusions: Although large falls or increases in BP are associated with a worse outcome, modest reductions may reduce death, and combined death or dependency, although the confidence intervals are wide and compatible with overall benefit or hazard.
PA.5. Hypokalaemic hypertension due to a rare cause
A 34-year old Bangladeshi lady had a 13 year history of refractory hypertension and associated hypokalaemia for at least 8 years. Severe hypertension during her third pregnancy required emergency LSCS. She was referred to the endocrine clinic during her fourth pregnancy. Her intra-partum cortisol and aldosterone were elevated, but levels normalised post-partum and urinary catecholamines were normal. The neuroendocrine secretory protein chromogranin A was elevated at 100 pmol/l (NRo 60) and post-partum CT showed a 9 cm heterogenous abdominal mass arising from the adrenal which was resected. Histology confirmed a tumour of adrenocortical origin with uncertain malignant potential due to size and cross-sectional imaging. However, with regards to Ki67 and cellular morphological features it appeared benign. Her hypertension and hypokalaemia resolved post-operatively, allowing withdrawal of all medications.
Serum saved pre-operatively revealed a markedly elevated 11-deoxycorticosterone (11 DOC) of 9741 pmol/l (Normal range 121-514 pmol/l) with normal corticosterone levels of 17.35 nmol/l (NR 5.78-23.12 nmol/l).
Deoxycorticosterone secreting tumours are extremely rare, 1 but both benign and malignant subtypes have been reported.
2 In a number of cases, both hypokalaemia and hypertension resolved after resection of tumour.
3 Post-operative 11 DOC is awaited and this will require follow up due to the uncertain malignant potential. Mitotane therapy has not currently been started. This diagnosis should be considered as a rare cause of hypokalaemic hypertension. Background: The current gold standard measure of large artery stiffness is the evaluation of aortic stiffness through measurement of carotid-femoral pulse wave velocity (PWV). In this study, we used a recent innovation in ultrasound, namely speckle tracking, to evaluate whether measurement of within carotid PWV could serve as an accurate and more user-friendly tool for the measurement of large vessel arterial stiffness. Methods and Results: In 12 female subjects, aged 18-35 years, we measured both carotid-femoral and carotid PWV using applanation tonometry (Compliors machine, Colson, France), and speckle tracking applied to common carotid digital looped B-mode images (Philips iU22 ultrasound system and QLAB version 7.0), respectively. As illustrated in the figure there was only a weak correlation between the two measures of stiffness.
Unexpectedly carotid PWV (mean±s.d., 0.6±0.3 m/s) was dramatically slower than carotid-femoral PWV (8.1 ± 0.8 m/s) (Po0.0001). Conclusions and Implications: PWV and stiffness may differ considerably along the arterial tree. Furthermore, because the current method for assessment of aortic stiffness includes a measure of the timing delay between arrival of the pulsation at the carotid and femoral arteries, slower carotid PWV likely results in a faster carotid-femoral PWV being erroneously calculated. Ultrasonic derived measurement of regional PWV using speckle tracking may prove to be a more accurate measure of large artery stiffness. Flow mediated dilation of the brachial or radial artery (FMD) in response to transient hyperaemic flow, the most widely used test of endothelial function, is only manifest after flow decays back to baseline. To determine whether this dissociation of flow and diameter might be explained by a reduction in transmural pressure generated by high flow we interrupted flow after cuff release before dilatation occurred. Studies were performed in 8 healthy subjects (aged 20-55 years). The brachial artery was cannulated and measurements repeated during brachial artery infusion of saline and the NO synthase inhibitor N G -monomethyl-L-arginine (L-NMMA, 8 mmol/min). Flow interruption 20 s after cuff release (during high flow but no dilatation) produced an immediate increase in radial artery diameter of 6.0±3.2% inhibited by L-NMMA to 1.0 ± 0.7% (Po0.01). Intra-arterial recording of radial blood pressure after cuff release demonstrated a fall in mean arterial pressure and hence in transmural pressure of B15 mm Hg at the time of peak hyperaemic flow. Modulation of transmural pressure within the radial artery by cuff inflation around the artery further demonstrated that this fall is sufficient to reduce radial diameter by an amount similar to FMD. These results suggest the flow-dependent, NO-dependent dilation is offset by a flow-induced fall in local arterial pressure and hence in transmural pressure obscuring the NO-dependent dilatation. Shear related NO release is likely to play a greater role in the physiological beat to beat regulation of arterial tone than that suggested by FMD. Abnormalities in microvascular circulations often predate or accompany other risk factors for cardiovascular disease. Changes in arterial properties due to ageing or the onset of disease manifest as changes in the morphology of blood velocity waveform. Interrogation of the blood velocity waveform therefore has the potential to reveal the presence of abnormalities.
PB.2. Flow mediated dilatation
PB.3. Wavelet analysis of blood velocity waveforms discriminates microvascular abnormalities in
Changes following O2 inhalation were characterized via blood velocity waveforms and retinal images. 25 patients with type I diabetes were compared with 20 matched controls. Maximum velocity waveforms were acquired in the carotid, central retinal and ophthalmic arteries at rest and during 100% O2 inhalation. Retinal images were captured from the right eye of each subject before and during O2 administration.
Blood velocity waveforms were analyzed using the discrete wavelet transform with principal component analysis. Standard parameters (resistive index, mean velocity) were also calculated. Vessel diameters were measured in the retinal images using a customized image analysis program.
Vessel diameter significantly decreased during O2 inhalation (controls m ¼ À9.8%, diabetics m ¼ À7.7%). Changes following O2 administration were noted in both resistive indices and wavelet parameters in the ophthalmic and central retinal arteries, but not the carotid. Wavelet parameters identified highly significant differences (Po0.0001) in the intervention's effect on controls compared to patients in the ophthalmic artery, which the resistive index failed to do.
Results suggest that interrogation of the blood velocity waveform beyond standard parameterization has the potential to discriminate treatment groups with improved power. Increasing significance toward the distal microcirculation suggests waveforms should be acquired close to the end organ. In this crosssectional study of 375 patients attending hospital BP clinics in Glasgow and Aberdeen we sought to (1) establish the prevalence of MAU (albumin:creatinine (ACR) 42.5 mg/l male; 43.5 mg/l female) and pre-MAU (ACR 1.2-2.5 mg/l male; 1.7-3.5 mg/l female) and (2) record CVD and LVH prevalence in these groups.
PB
Methods:
The following data were collected by research nurses: age, gender, BP, BMI, fasting glucose, lipids, creatinine, ECHO or ECG evidence of LVH, history of CVD (IHD, stroke, PVD, AF) and drug history (especially whether on ACEI or ARB). Urine samples (if free of leukocytes and nitrates) were sent for laboratory measurement of ACR. Patients with diabetes were excluded.
Results: Mean age and BP were 56 yrs and 141/ 87 mm Hg, and 71% were on ACEI/ARB. 12.5% had MAU and 20.3% had pre-MAU. Circulating blood may represent a 'surrogate' tissue from which informative molecular signatures can be obtained easily, by applying microarrays technologies to profile blood-derived RNA. This study investigated the dynamic changes in whole blood gene expression in patients with coronary artery disease (CAD) during a cardiac rehabilitation programme. Ten male patients with CAD were enrolled in a rehabilitation programme for 10 weeks after coronary artery bypass graft surgery. Blood was collected before and after completion of the programme. Total RNA gene expression and miRNA profiling were studied. Pathway analysis was performed using Ingenuity Pathway Analysis software.
Expression analysis identified 449 genes downregulated and 196 up-regulated after rehabilitation (false discovery rate [FDR]o0.05). Biological pathways including glucocorticoid receptor signalling and oxidative phosphorylation/mitochondrial function were found to be consistently modulated. We also identified down regulation of certain genetic markers of cardiovascular disease (catalase, caspases 3 and 8). Analysis of miRNA expression revealed several differentially expressed miRNA (FDRo0.05) after rehabilitation, including hsamiR-92a (FDR ¼ 0.02) and 92b (FDR ¼ 0.01). Global analysis of their predicted gene targets demonstrated a significant mean reduction in expression of genes including target regions, versus those without target regions (P ¼ 2.2 Â 10 À16 ). Moreover, integration of microarray and miRNA data revealed direct regulation of specific targets of hsa-miR-92b, including caspase-3 and NDUFA1, a component of mitochondrial Complex I.
We identified differentially expressed miRNAs, differentially regulated genes and disrupted pathways affecting several parameters related to cardiovascular function following rehabilitation programme, offering a novel non-invasive strategy to unravel the modifiable pathways and possible therapeutic targets. Blood pressure (BP) varies depending on which arm it is measured in. This may be a function of peripheral vascular disease. Guidelines recommend consecutive measurements in both arms with use of the highest pressure in cases of discrepancy. We compared BP measured in both arms with ambulatory measurement (ABPM) over 24 h. Consecutive patients attending a single hypertension clinic were enrolled. Each person had BP measured in right and left arms (no particular order) followed by ABPM. Comparisons of BPs were made using bootstrapping to derive confidence intervals and significance levels because of non-normal distributions. 784 patients underwent consecutive investigation and 710 results were available for analysis. 39.3% (279) had a BP X10 mm Hg difference between each arm of whom 56% (156) had a higher BP (X10 mm Hg) in the right arm than the left. Taking the arm with the highest reading, there was a 25.1 mm Hg difference between this and daytime systolic ABPM compared to 15.5 mm Hg if the lowest reading was taken (mean difference and bootstrap 95% CI ¼ 9.6 mm Hg (9.0-10.3)). Comparing the BP from the right arm with daytime ABPM found a 20.7 mm Hg difference as opposed to 19.9 mm Hg difference if the left was compared. Compared with ABPM use of the measurement in the highest arm appears to over estimate true mean blood pressure. This may be due to the white coat effect which reduces on repeat measurement. Where a large inter-arm BP difference is detected, health care professionals should re-measure the BP in the original arm. 35 patients with well controlled type I diabetes and no complications were compared to 38 age and sex matched controls (all subjects aged 18-55 years). 10 diabetics were re-studied after treatment with ramipril. Maximum blood velocity waveforms in the brachial artery were recorded before, during and after inflation of a cuff on the forearm. Arterial compliance was calculated by measuring diameter excursions, and flow-mediated dilatation (FMD) of the brachial artery calculated. Pulse waveforms were analysed using a wavelet-based approach, and comparisons made using a 4 factor method.
PC
PC.2. Comprehensive interrogation of pulse waveforms identifies hidden microvascular abnormalities in
When the cuff was inflated, significant differences were noted between the groups' waveforms in factor 3 (P ¼ 0.015). This may reflect the fact that local artery compliance was higher in controls (P ¼ 0.042). FMD was significantly impaired in diabetics (mean 7.64% in controls, 4.19% in diabetics, P ¼ 0.024). When the cuff was released and the waveforms progressed towards baseline, significant differences were apparent in factor 2 for pulses 2 through 10 (P ¼ 0.03). It took longer for the waveshape to normalise in diabetics than controls (recovery half life 32.1 pulses in controls, 38.3 in diabetics). Treatment with ramipril normalised this index.
Abnormalities in blood velocity waveforms were present in patients with diabetes. ACE inhibitors may be helpful in correcting microvascular abnormalities in diabetes.
PC.4. Selective dilatation of muscular arteries is an effective strategy to reduce central pulse pressure in women and does not act through reduction in central arterial stiffness M Cecelja, K Patel, T Spector and P Chowienczyk King's College London, London, United Kingdom Background: Central arterial pulse pressure (cPP) can be partitioned into the height of the first systolic shoulder (P1), thought to be determined by a forward pressure wave, and augmentation pressure (DP aug ) from reflected pressure waves. In women, elevated cPP arises mainly from an increase in DP aug rather than P1. Objectives: To determine whether glyceryl trinitrate (GTN) has a selective action to reduce DP aug through dilation of muscular arteries. Methods: Twenty-six women from the TwinsUK registry aged 44-75 years were studied. Central pressure waveforms were estimated from transformed radial waveforms using the SphygmoCor system, calibrated from brachial blood pressure. Carotidfemoral pulse wave velocity (PWV) was determined with the same system. Diameters of the abdominal aorta, brachial, carotid and femoral arteries were measured by B-mode ultrasound. Measurements were made after 15 min rest supine and repeated 5 min after GTN (400 mg sublingual). Results: GTN had little effect on diastolic blood pressure (reduction from 74.3±7.1 to 70.2±6.2 mm Hg) but reduced cPP from 43.5 ± 10.7 to 33.6 ± 8.0 mm Hg (Po0.001). This decrease was entirely explained by a decrease in DP aug (15.2±6.7 to 5.8±4.1, Po0.001) with no significant change in P1. There was no significant change in aortic distensibility as measured by carotid-femoral PWV or in abdominal aortic diameter. Diameter of the carotid, femoral, and brachial arteries increased by 4.9, 4.9, and 16.9%, respectively (Po0.001). Conclusion: These results suggest that, in women, selective dilatation of muscular arteries is an effective strategy to reduce cPP through a reduction in wave reflection rather than in central arterial stiffness. Vascular structural and mechanical alterations in hypertension and aging contribute towards cardiovascular morbidity/mortality. The aim of this study was to determine whether integrin-extracellular matrix (ECM) interactions contribute towards altered vascular structure/mechanics. The effect of disintegrin-treatment (kistrin, or echistatin), ex-vivo, on second order mesenteric resistance artery structure and mechanics, was assessed using wire-myography, in Spontaneously Hypertensive (SHRs) and WistarKyoto rats (WKYs). Vascular integrin aV and a5 expression were also quantified. Arteries from 8 and 15 week-old SHRs showed an increased media/lumen ratio (470%; Po0.01) but constant media crosssectional area (MCSA) versus WKYs. However, both the media/lumen ratio (440%; Po0.05) and MCSA (4128%, Po0.01) were significantly increased in 1 year-old SHRs versus WKYs. Vascular stiffness was increased in 8 week-old SHRs versus WKYs but was similar in 15 week-old and 1 year-old SHRs versus WKYs, despite increased integrin aV and a5 expression in these latter two groups. Disintegrin-treatment of arteries did not alter structure or mechanics in SHRs. With aging in WKYs, media thickness and MCSA were increased (by 425% in 15 week-old and 1 year-old WKYs versus 8 week-old WKYs, Po0.05) but stiffness was unaltered. In addition integrin aV and a5 expression were unchanged. In WKYs at all ages, vascular structure remained unaltered by disintegrin-treatment; however, stiffness was significantly reduced with echistatin-treatment versus controltreatment (Po0.05), suggesting that integrin-ECM interactions contribute towards passive stiffness of arteries in WKYs. Further insight into the influence of integrin-ECM interactions on vascular structure/mechanics will contribute towards a better understanding of hypertension and age-related cardiovascular complications. Introduction: Fibrinogen, a major determinant of blood viscosity, is an acute phase protein associated with cardiovascular disease. We studied the association of hypertension with single nucleotide polymorphisms (SNPs) in the gene encoding fibrinogen beta chain (FGB). Methods: Three tagging SNPs (rs1025154, rs4220 and rs1044291) were selected from the HapMap database on Han Chinese. Genotypes were determined in 1375 unrelated subjects from the Hong Kong Cardiovascular Risk Factor Prevalence Study cohort. There were 210 and 372 hypertensive subjects at baseline and at the six-year follow-up, respectively. Results: Among the 3 SNPs, rs4220 showed an association with hypertension at baseline (OR ¼ 1.49, P ¼ 0.004) and at follow-up (OR ¼ 1.28, P ¼ 0.024), after adjusting for age, sex, current smoking, drinking and education. This SNP was associated with higher plasma fibrinogen level (b ¼ 0.15, Po0.001 at baseline and b ¼ 0.13, Po0.001 at follow-up). The association with hypertension remains significant after further adjusting for body mass index and fibrinogen level (OR ¼ 1.43, P ¼ 0.014 at baseline; OR ¼ 1.29, P ¼ 0.038 at follow-up). Conclusion: The SNP rs4220 in FGB, which leads to substitution of arginine by lysine at position 448, is associated with plasma fibrinogen level and hypertension independently in Hong Kong Chinese. This suggests that fibrinogen may be causally linked to hypertension, directly or indirectly, and that elevated fibrinogen level in hypertension is not merely a consequence of elevated blood pressure. Objectives: Recent studies have underlined the growing importance of differential expression of miRNAs as regulatory molecules in health and disease. The aim of this study was to identify miRNA content of human kidneys in normotensive and hypertensive individuals. Additionally, miRNA screening was performed on kidneys from hypertensive (SHRSP) and normotensive (WKY) rats, to evaluate the conserved nature of candidate miRNAs. Methods: Total and miRNA was extracted from medullary tissue from hypertensive and normotensive (n ¼ 10) age and sex matched individuals as previously described 1 . Whole kidneys from male, 5 and 16 week-old SHRSP and WKY animals (N ¼ 4) were similarly processed. Screening for miRNA was performed using micro-fluidic paraflow technology. Results: Profiling identified 29 differentiallyexpressed miRNA in human kidneys (16 up-regulated and 13 down-regulated in hypertensives; Po0.05). Nine miRNA were differentially expressed between SHRSP and WKY kidney tissue at 16 weeks, and 3 at 5 weeks. Hsa-miR-192 and hsa-miR-30c were significantly increased in kidney tissue from both human hypertensive patients and SHRSP rats, relative to their normotensive controls. Bioinformatic analysis predicted downstream targets of differentially-expressed miRNA (ranked by number of predicted 'seed' regions within 3 0 UTR). Candidates included NEDD4, SMAD2, BMPR2 and multiple members of the FGF family, which have been previously linked to renal pathology.
1 Canonical clustering revealed FGF, TGF-beta and BMP signalling to be potentially highlyregulated by hsa-miR-192 and hsa-miR-30c. Conclusions: We have identified several differentially expressed renal miRNAs in hypertensive patients, including two which show a conserved pattern with a well-characterised model of human essential hypertension. Circulation 2007; 116: 1915-24. PD.3. High fidelity phenotypic analysis of chromosome 3 congenic strains reveals independent loci for haemodynamic regulation HHC Koh-Tan, D Graham, J McClure, K Gilday and AF Dominiczak University of Glasgow, Glasgow, United Kingdom Objective: We have identified blood pressure quantitative trait loci mapping to rat chromosomes 2 and 3 in an F2 cross derived from SHRSP and WKY strains. Generation of a double chromosome 2/3 congenic strain previously demonstrated almost complete reversal of SHRSP haemodynamic profiles. This study aimed to generate a single chromosome 3 congenic strain to investigate putative interactions between loci on the implicated chromosomes. Methods: A marker-assisted breeding strategy was used to generate the SP.WKYGla3a congenic strain (D3Mgh16-D3Rat114), using SHRSP as recipient and WKY as the donor strain. Haemodynamic measurements (systolic, diastolic, pulse pressure, heart rate and motor activity) were carried out using radiotelemetry during baseline and salt-loaded periods. Results: In the SP.WKYGa3a strain (n ¼ 5) salt-loaded systolic (197.9±5.4 mm Hg), diastolic (138.8± 4.1 mm Hg) and pulse pressure (59.0 ± 1.8 mm Hg) were significantly reduced compared to SHRSP (n ¼ 21) (240.4 ± 4.4 mm Hg, F ¼ 126.8, P ¼ 0.0001, 178.0±5.6 mm Hg, F ¼ 60.6, P ¼ 0.0001 and 66.6± 1.8 mm Hg, F ¼ 9.63, P ¼ 0.001 respectively) repeated measures ANOVA. Heart rate was significantly increased in SP.WKYGla3a compared to SHRSP (368.8±6.6 vs 355.7±5.5 beats/min, F ¼ 6.55, P ¼ 0.018). Pulse pressure diurnal variation observed in SHRSP during salt-loading was abolished in the SP.WKYGla3a strain (P ¼ 0.001, one-way ANOVA). Analysis using 2 Â 2 factorial ANOVA indicates independent additive effects of the chromosome 2 and 3 congenic intervals for all haemodynamic parameters. Motor activity was not significantly different between strains. Conclusions: Blood pressure loci within the chromosome 3 congenic interval regulate diurnal pulse pressure variability and act independently to loci on chromosome 2. These strains will allow interrogation of complex gene-gene, gene-environment interactions contributing to salt-sensitive hypertension in SHRSP. Inflammatory cells are involved in the pathogenesis of cardiovascular disease, but the underlying mechanisms are largely unknown. We examined expression of genes in circulating mononuclear cells to discover disease specific pathways.
1.
Mononuclear cells were extracted from whole blood of patients with coronary artery disease (CAD; n ¼ 44) and healthy control subjects (n ¼ 44) by Ficoll gradient and superoxide production was measured using EPR spectroscopy. Total RNA was isolated for gene expression profiling (Illumina, Human WG-6 v3.0 chip). Ingenuity Pathway Analysis (IPA) was used to visualise networks of differentially expressed genes (n ¼ 12 per group). Serum samples were analysed using multiplexing technology (Luminex xMAP).
Of 1644 differentially expressed genes, 852 were up and 812 down regulated in patients with CAD vs control subjects. Differential gene expression was particularly present in extravasation/adhesion and inflammation related pathways with TNF (1.5 fold, false discovery rate [FDR] 0.001), IL8 (1.7 fold, FDR o0.001), MMP9 (1.7 fold, FDR o0.001) and VCAM1 (1.5 fold, FDR 0.01) being up and TIMP1 (À1.5 fold, FDR 0.01) down regulated in patients with CAD. Serum levels of TNF-a (0.7 ± .09 vs 0.3 ± 0.4 pg/ml), IL-8 (4.6±5.0 vs 2.4±2.3 pg/ml), VCAM-1 (79±25 vs 66±20 ng/ml), and superoxide production from mononuclear cells (2.5 ± 1.7 vs 1.8 ± 0.8 nmol/min/ 10 6 cells; P ¼ 0.03) were greater in patients with CAD (all Po0.05).
Our data suggest that up regulation of inflammation and cell adhesion related genes in mononuclear cells contributes to the pro-inflammatory milieu in patients with CAD. Gene expression profiling and pathway analysis identifies pathogenetic mechanisms and potential targets for therapeutic and preventative strategies.
PD.5. Angiotensin1-9 antagonises prohypertensive signalling in cardiomyocytes via the angiotensin type 2 receptor M Flores-Muñ oz, AH Baker and SA Nicklin University of Glasgow, Glasgow, United Kingdom
The angiotensin converting enzyme (ACE) homologue, ACE2 metabolizes AngII to Ang1-7, decreasing AngII and increasing Ang1-7. Ang1-7 antagonize AngII antagonist via the receptor MAS. ACE2 also converts AngI to Ang1-9. Ang1-9 is thought to be a substrate for further Ang1-7 generation via ACE. We investigated Ang1-9 and Ang1-7 function in cardiomyocyte hypertrophy in rat neonatal (H9c2) and primary adult rabbit left ventricular cardiomyocytes.
Cardiomyocyte hypertrophy was stimulated with AngII or vasopressin (AngII: 149.7±15.6 nm; vasopressin: 160.1 ± 13.2 nm; no stimulation: 112.3 ± 13.5 nm, Po0.05). Both Ang1-9 and Ang1-7 blocked hypertrophy induced by either agonist. We tested whether Ang1-9 was converted to Ang1-7 via ACE, using the ACE inhibitor captopril. Ang1-9 effects were not inhibited by captopril, suggesting Ang1-9 acts independently of Ang1-7. Next, we investigated receptor signalling via the angiotensin type 1 and type 2 receptors (AT1R, AT2R) and MAS. The AT1R antagonist losartan blocked AngII, but not vasopressin-induced hypertrophy. Additionally, losartan did not block the antihypertrophic effects of Ang1-9 on vasopressin-stimulated cardiomyocytes, suggesting a lack of involvement of AT1R. We investigated MAS signalling using the antagonist A779, which efficiently blocked Ang1-7 0 s antihypertrophic effects without affecting Ang1-9, further suggesting Ang1-9 signalled independently. The AT2R antagonist PD123,319 abolished Ang1-9's antihypertrophic effecst, without affecting Ang1-7, suggesting Ang1-9 signals via the AT2R.
In summary, Ang1-9 and Ang1-7 inhibit cardiomyocyte hypertrophy induced by AngII or vasopressin. Importantly we ascribe a direct biological role for Ang1-9 as a RAS hormone, signalling via the AT2R. This has implications for understanding RAS function and identification of new therapeutic targets in cardiovascular disease. Results: 83 children aged 1-18 (median 10) years were studied with 61% (51) having a diagnosis of RVD. Main renal artery disease, intrarenal disease and both main and intra-renal artery disease were present in 25, 14 and 12 patients respectively. The isotope study accurately diagnosed RVD, confirmed by DSA, in 47% (24 of 51) children with 8 false positive studies. The sensitivity, specificity, positive and negative predictive values of the isotope study to predict RVD were 48, 73, 76, and 51%, respectively. Conclusions: Pre-and post-captopril renal scintigraphy was unable to predict RVD in children.
